Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the best mid cap pharma stocks to buy. On July 22, Lantheus Holdings announced the completion of its acquisition of Life Molecular Imaging Ltd./LMI, which is a subsidiary of Life Healthcare Group Holdings Ltd. As a result of this acquisition, Dr. Ludger Dinkelborg, formerly CEO and Managing Director of LMI, has been appointed as the Head of Research and Development at Lantheus, effective August 1 this year.
In his new role, Dr. Dinkelborg will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers Solutions, reporting directly to the CEO. This acquisition brings Neuraceq (florbetaben F18 injection) into Lantheus’s portfolio. Neuraceq is a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in adults being evaluated for Alzheimer’s disease and other causes of cognitive decline, as well as for selecting patients indicated for amyloid beta-directed therapy.
A biopharmaceutical laboratory showcasing the latest drug therapy treatments for liver diseases.
The FDA approved Neuraceq on June 23 this year. The transaction also provides Lantheus with a robust commercial infrastructure for Alzheimer’s disease radiodiagnostics, advanced R&D capabilities, and an established international presence. Important safety information regarding Neuraceq includes risks for image interpretation errors and other potential inaccuracies.
Lantheus Holdings Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
